Veronique Lecault - 16 May 2022 Form 4 Insider Report for AbCellera Biologics Inc. (ABCL)

Role
Chief Operating Officer, Director
Signature
/s/ Tryn Stimart, attorney-in-fact
Issuer symbol
ABCL
Transactions as of
16 May 2022
Net transactions value
+$1,267,780
Form type
4
Filing time
17 May 2022, 15:07:35 UTC
Previous filing
01 Mar 2022
Next filing
05 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABCL Common Shares Purchase $1,267,780 +200,000 +13% $6.34 1,770,122 16 May 2022 Direct F1
holding ABCL Common Shares 7,155,008 16 May 2022 See Footnote F2
holding ABCL Common Shares 273,630 16 May 2022 See Footnote F3
holding ABCL Common Shares 61,580 16 May 2022 By spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $6.22 to $6.50. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.
F2 These shares are held by Pacific Swell Capital Corp ("Pacific Swell"). The Reporting Person is a director of Pacific Swell and shares voting and dispositive power with respect to the shares held by Pacific Swell. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein.
F3 These shares are held by Slomo Family Trust. The Reporting Person is a co-trustee of the Slomo Family Trust. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of her indirect pecuniary interest therein.